Ampio Pharmaceuticals, Inc. to Hold Fourth Quarter 2021 Earnings and Business Update Call
Ampio Pharmaceuticals, Inc. (AMPE) will host its fourth quarter earnings and business update call on March 29, 2022, at 4:30 PM EST. The call aims to provide insights into the company's financial performance and future direction. Ampio focuses on immunomodulatory therapies for osteoarthritis pain, with its lead product, Ampion™, backed by a robust patent portfolio and potential FDA market exclusivity through the Biologics Price Competition and Innovation Act. Investors are encouraged to join the call for detailed updates.
- Ampio's lead therapy, Ampion™, has robust patent protection until 2037.
- Potential for 12-year FDA market exclusivity as a novel biologic.
- Uncertainty regarding regulatory approvals and clinical trial outcomes.
ENGLEWOOD, Colo., March 23, 2022 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunomodulatory therapies for the treatment of pain resulting from osteoarthritis, announced that the Company will be hosting its fourth quarter earnings and business update call March 29 at 4:30pm EST.
Conference Call Details
Date/Time: March 29, 2022, at 4:30 pm EST
Conferencing Link:
https://event.on24.com/wcc/r/3683372/9CD2C8B658E56541C487F44C34E897BB
Access Code: 66744
Canada dial-in number (Toll Free): | 1 833 950 0062 |
Canada dial-in number (Local): | 1 226 828 7575 |
US dial-in number (Toll Free): | 1 844 200 6205 |
US dial-in number (Local): | 1 646 904 5544 |
Access code: | 931547 |
*Participants will need to enter the participant access code before being met by an operator
In order to submit questions, participants must have Internet connectivity, as questions will only be addressed via the webcast. The conference call line will be in listen-only mode.
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company primarily focused on the advancement of immunology-based therapies for the treatment of pain resulting from osteoarthritis. Ampio's lead drug, Ampion™, is backed by an extensive patent portfolio with intellectual property protection extending through 2037 and may be eligible for 12-year FDA market exclusivity upon approval as a novel biologic under the Biologics Price Competition and Innovation Act (BPCIA).
Ampio's statements in this press release and the webinar that are not historical fact, and that relate to future plans or events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include statements regarding Ampio's expectations with respect to Ampion and its classification, as well as those associated with regulatory approvals and other FDA decisions, the Biological License Application (BLA), the ability of Ampio to enter into partnering arrangements, clinical trials and decisions and changes in business conditions and similar events, the ability to receive regulatory approval to conduct clinical trials, that Ampion may be used to treat ARDS induced by COVID-19, all of which are inherently subject to various risks and uncertainties. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including without limitation, under Ampio's Annual Report on Form 10-K and other documents filed with the Securities and Exchange Commission. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.
Investor and Media Contacts:
Tony Russo or Nic Johnson
Russo Partners
tony.russo@russopartnersllc.com
nic.johnson@russopartnersllc.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ampio-pharmaceuticals-inc-to-hold-fourth-quarter-2021-earnings-and-business-update-call-301508715.html
SOURCE Ampio Pharmaceuticals, Inc.
FAQ
When is Ampio Pharmaceuticals' earnings call?
What is the focus of Ampio Pharmaceuticals?
What product is Ampio Pharmaceuticals developing?
How can I access Ampio Pharmaceuticals' earnings call?
What risks are associated with Ampio Pharmaceuticals' future plans?
